Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAESAR
2024-516956-16-01Phase 3Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of capecitabine in salivary duct carcinoma (SDC), sponsored by Radboud University Medical Center. Primary endpoint: Best overall response rate. Planned start Mar 2025; status: authorised.
02
Drugs
capecitabine
03
Conditions
salivary duct carcinoma (SDC)
Beyond the preview
Go deeper on 2024-516956-16-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516956-16-01.